Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

54.84 -0.07 (-0.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,542,979
Open 55.21
Bid (Size) 54.62 (10)
Ask (Size) 55.00 (1)
Prev. Close 54.91
Today's Range 54.76 - 55.72
52wk Range 52.65 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
PhaseBio Might Have To Return Global Rights To Its Lead Program
 
Via Benzinga
7 Large-Cap Stocks With Sustained Dividend Growth Potential
Large-cap stocks with dividend growth potential have robust cash flows and are likely to increase their dividends in the coming years. 
Via InvestorPlace

Performance

YTD
-5.95%
-5.95%
1 Month
-12.09%
-12.09%
3 Month
-16.85%
-16.85%
6 Month
-17.92%
-17.92%
1 Year
-8.69%
-8.69%

More News

Read More
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Via InvestorPlace
US Stock Futures Rise Ahead Of Economic Reports, Fed Speakers; Crude Oil Rises 1%
Via Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
Via Benzinga
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
Via Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
Via Benzinga
European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders
Via Benzinga
3 Medical Stocks Displaying Remarkable Relative Strength In 2022
Via Talk Markets
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Via Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
From Alexion
Via Business Wire
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Via Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
Via Benzinga
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
From AstraZeneca
Via Business Wire
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
Via Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.